Mo-99 Ready To Be Produced At Darlington NPP The Darlington Nuclear Power Plant, located in Canada and operated by Ontario Power Generation (OPG), is now ready to produce life-saving Molybdenum-99 (Mo-99) isotopes, Laurentis Energy Partners and BWXT Medical Ltd announced last week. Thanks to the installation and initial commissioning of an innovative isotope system made…
Framatome and Exelon Signed A MoU To Strengthen Cobalt-60 Production Framatome (ENS Corporate Member) and Exelon Generation recently announced the signature of a Memorandum of Understanding to develop solutions to produce Cobalt-60 in Pressurized Water Reactors (PWR) operated by Exelon Generation in the US. Cobalt-60 is a radioisotope produced in nuclear reactors out of natural…
Westinghouse and EDF To Collaborate To Produce Cobalt-60 Radioisotope During the last World Nuclear Exhibition, Westinghouse Electric Company and EDF (both ENS Corporate Members) signed a Memorandum of Understanding to produce Cobalt-60 radioisotope in select Pressurized Water Reactors (PWR) owned and operated by EDF in France. Cobalt-60 plays a critical role in the safety of medical…
HFR 60th Anniversary And The Rising Demand For Radiopharmaceuticals The demand for medical treatments is rising sharply, partly due to the increased incidence of cancer. In the past year, 115,000 new cases of cancer have been diagnosed in the Netherlands, 13,000 of which prostate cancer. Consequently, NRG|PALLAS is seeing an increase in the demand for…
SCK CEN And IBA Cooperate To Enable The Production Of Actinium-225 SCK CEN – Belgian Nuclear Research Center (ENS Corporate Member) and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announced a strategic R&D partnership to enable the production of Actinium-225 (225Ac), a novel radioisotope which has significant potential in…
SCK CEN And Quirem Medical Start Producing Ho-166 Microspheres At BR2 Reactor SCK CEN and Quirem Medical announce the first production of holmium-166 microspheres for patient use at the BR2 reactor in Mol, Belgium. A first clinical QuiremSpheres® patient procedure took place with radioactive holmium-166 microspheres, an innovative product for treating liver cancer patients. QuiremSpheres is…
NRG delivers 10 patient doses of Lutetium-177 Last week, NRG has delivered lutetium for the first time to an academic hospital and two pharmaceutical parties this month. Sander de Groot, program manager medical isotopes at NRG: “This isotope offers a great perspective for the effective treatment of various cancer indications and with limited side effects.…
NRG And PALLAS Together For A Shared, Innovative Future NRG and PALLAS aim to fuse together as one organisation, as announced by Bertholt Leeftink, CEO NRG/PALLAS. “By combining our forces, we are able to make large steps forward in the development and production of nuclear medicines used for diagnostic purposes and for the treatment of…
Lutetium-177, The Increasing Production Of A Promising Radioisotope Lutetium-177 (Lu-177) is considered to be one of the most promising radioisotopes. Radiopharmaceuticals based on Lu-177 have already demonstrated excellent therapeutic performance in several applications, as prostate cancer and gastroenteropancreatic neuroendocrine tumors treatment. Thanks to its efficient performances and results, the demand for Lu-177 is growing. Several…